Quantcast

Latest photodynamic therapy Stories

2010-07-28 00:06:21

NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer.

2010-06-24 05:30:00

All Claims Upheld at Conclusion of Successful Reexamination Process WILMINGTON, Mass., June 24 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office (USPTO) has completed its re-examination of US Patent No.

2010-05-13 11:04:00

WILMINGTON, Mass., May 13 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, today announced that its Annual Meeting of Shareholders will be held on Thursday, July 29, 2010 at 11:00 AM at the Company's offices at 25 Upton Drive, Wilmington, MA.

2010-05-11 08:30:00

TSX Venture: QPT EDMONTON, May 11 /PRNewswire-FirstCall/ - Quest PharmaTech Inc.

2010-05-11 05:30:00

WILMINGTON, Mass., May 11 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the first quarter ended March 31, 2010. Highlights for the first quarter include: Total product revenues were $8.7 million for the quarter, representing a $1.6 million...

2010-05-07 05:30:00

WILMINGTON, Mass., May 7 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U(®), Blue Light Photodynamic Therapy Illuminator.

2010-04-29 07:59:00

MONACO, April 29, 2010 /PRNewswire/ -- At the 10th Congress of the European Society for Photodynamic Therapy (Euro PDT), held in Monaco on March 12-13, 2010, Professor Lasse Braathen (Tromso, Norway), president of the Euro PDT, described the current state of topical photodynamic therapy, a revolutionary treatment for precancerous skin lesions and superficial skin carcinomas.

2010-03-09 07:30:00

WILMINGTON, Mass., March 9 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq: DUSA), a specialty pharmaceutical company focused primarily on the development and marketing of its Levulan(®) Photodynamic Therapy (PDT) technology platform for the prevention and treatment of dermatological skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Roth 22nd Annual OC Growth Stock Conference.

2010-03-05 06:00:00

WILMINGTON, Mass., March 5 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(® )(NASDAQ GM: DUSA), a specialty pharmaceutical company focused on dermatology, will unveil an ergonomically enhanced BLU-U(®) Blue Light Photodynamic Therapy Illuminator at this year's American Academy of Dermatology (AAD) meeting in Miami, Florida, March 5-9.


Word of the Day
immane
  • Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.
The word 'immane' comes from the Latin word 'immanis', 'enormous'.
Related